Xuanzhu Biopharmaceutical Co., Ltd.

Xuanzhu Biopharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
Holding, Subsidiary
Established
2018-09-05
Employees
251
Market Cap
-
Website
http://www.xuanzhubio.com
Clinical Trials
Related News

A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human

Phase 1
Not yet recruiting
Conditions
Healthy Volunteers
Interventions
Drug: [14C]XZP-3621
First Posted Date
2023-05-01
Last Posted Date
2023-05-01
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
6
Registration Number
NCT05836805
Locations
🇨🇳

The First Affiliated Hospital of Suzhou Universiy, Suzhou, Jiangsu, China

A Study of KM501 in Patients With Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: KM501
First Posted Date
2023-04-07
Last Posted Date
2023-04-07
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
96
Registration Number
NCT05804864
Locations
🇨🇳

Tianjin Cancer Hospital, Tianjin, Tianjin, China

A Study of XZB-0004 in Patients With Solid Tumors

Phase 1
Recruiting
Conditions
NSCLC
Advanced Solid Tumor
Interventions
Drug: XZB-0004
First Posted Date
2023-03-16
Last Posted Date
2024-10-28
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
128
Registration Number
NCT05772455
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

A Study of KM602 in Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumor
Interventions
Biological: KM602
First Posted Date
2023-03-13
Last Posted Date
2023-03-13
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
38
Registration Number
NCT05766527
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

Phase 1
Not yet recruiting
Conditions
MDS
AML
Interventions
Drug: XZB-0004
First Posted Date
2023-02-23
Last Posted Date
2023-02-23
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
82
Registration Number
NCT05740917
Locations
🇨🇳

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

First Posted Date
2022-11-03
Last Posted Date
2022-11-03
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
156
Registration Number
NCT05604261
Locations
🇨🇳

Shanghai Changhai Hospital, Shanghai, Shanghai, China

Drug-drug Interaction Study of XZP-3621 Tablet

First Posted Date
2022-10-19
Last Posted Date
2022-10-19
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
72
Registration Number
NCT05586568
Locations
🇨🇳

The Affiliated Hospital of Qingdao University, Qingdao, Shan Dong, China

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

Phase 2
Not yet recruiting
Conditions
ALK-positive NSCLC
Interventions
Drug: XZP-3621
First Posted Date
2022-08-01
Last Posted Date
2022-08-01
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
190
Registration Number
NCT05482087
Locations
🇨🇳

Jilin Province Cancer Hospital, Jilin, Chang Chun, China

A Clinical Trial of XZP-3287 for Material Balance

Phase 1
Conditions
Healthy Male Subjects
Interventions
Drug: [14C]XZP-3287
First Posted Date
2022-07-28
Last Posted Date
2022-07-28
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
10
Registration Number
NCT05478109
Locations
🇨🇳

Beijing Gaobo Boren Hospital, Beijing, Beijing, China

A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumor
Interventions
Biological: KM257 Bispecific antibody
First Posted Date
2022-04-11
Last Posted Date
2022-04-11
Lead Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Target Recruit Count
232
Registration Number
NCT05320874
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy